Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber
Peter Arne
PA
Enderlein
Elaine
E
Homey
Bernhard
B
Muller
Anja
A
Boelke
Edwin
E
Budach
Wilfried
W
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D001415:Back; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D018714:Radiotherapy, Adjuvant; D012867:Skin / Q000187:drug effects / Q000528:radiation effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor